stem cells in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Lanzoni, 2021 0.14 [0.02; 0.96]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
0.22 [0.05 ; 0.97 ] Lanzoni, 2021, Shi, 2020, Shu, 2020 3 0% 165 moderate not evaluable deathsdetailed results Lanzoni, 2021 0.11 [0.01; 0.93]
Shi, 2020 0.53 [0.01; 27.55]
Shu, 2020 0.38 [0.02; 8.14]
0.20 [0.04 ; 0.98 ] Lanzoni, 2021, Shi, 2020, Shu, 2020 3 0% 165 moderate not evaluable deaths (time to event analysis only)detailed results Lanzoni, 2021 0.11 [0.01; 0.93]
0.11 [0.01 ; 0.93 ] Lanzoni, 2021 1 0% 24 NA not evaluable clinical deteriorationdetailed results Shu, 2020 0.27 [0.01; 5.58]
0.27 [0.01 ; 5.58 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvementdetailed results Shu, 2020 10.27 [1.17; 90.18]
10.27 [1.17 ; 90.18 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvement (14-day)detailed results Shu, 2020 10.27 [1.17; 90.18]
10.27 [1.17 ; 90.18 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvement (28-day)detailed results Shu, 2020 3.68 [0.18; 75.54]
3.68 [0.18 ; 75.54 ] Shu, 2020 1 0% 41 NA not evaluable clinical improvement (7-day)detailed results Shu, 2020 6.72 [1.50; 30.07]
6.72 [1.50 ; 30.07 ] Shu, 2020 1 0% 41 NA not evaluable mechanical ventilationdetailed results Shu, 2020 0.59 [0.02; 14.04]
0.59 [0.02 ; 14.04 ] Shu, 2020 1 0% 41 NA not evaluable recoverydetailed results Lanzoni, 2021 3.46 [1.05; 11.35]
3.46 [1.05 ; 11.35 ] Lanzoni, 2021 1 0% 24 NA not evaluable serious adverse eventsdetailed results Lanzoni, 2021 0.10 [0.01; 0.69]
Shi, 2020 1.08 [0.04; 32.96]
0.21 [0.02 ; 1.86 ] Lanzoni, 2021, Shi, 2020 2 29% 124 moderate not evaluable adverse eventsdetailed results Lanzoni, 2021 0.18 [0.02; 1.95]
Shi, 2020 0.88 [0.38; 2.03]
Shu, 2020 2.48 [0.05; 132.54]
0.77 [0.36 ; 1.68 ] Lanzoni, 2021, Shi, 2020, Shu, 2020 3 0% 165 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 03:41 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 534
- roots T: 290
